GRAIL is a life sciences company whose mission is to detect cancer early when it can be cured. GRAIL combines the power of high-intensity sequencing (ultra-broad and ultra-deep sequencing), leading-edge computer science, and large population-scale clinical studies to enhance the scientific understanding of cancer biology and develop a blood test for early-stage cancer detection.
Market
Cancer Detection
Location
Menlo Park,
California,
USA
Coinvestors
Amazon.com, ARCH Venture Partners, Bristol-Myers Squibb, Celgene Corporation, Johnson & Johnson Innovation, McKesson Ventures, Merck Ventures, Tencent Holdings, Varian Medical Systems